Predicted protein targets (top 15)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | THRA | P10827 | 6/20 | 0.57 |
| ▸ | THRB | P10828 | 5/20 | 0.57 |
| ▸ | KMT2A | Q03164 | 2/20 | 0.50 |
| ▸ | ALDH1A1 | P00352 | 3/20 | 0.49 |
| ▸ | LMNA | P02545 | 2/20 | 0.49 |
| ▸ | KDM4E | B2RXH2 | 1/20 | 0.49 |
| ▸ | TAAR1 | Q96RJ0 | 1/20 | 0.49 |
| ▸ | PARP1 | P09874 | 1/20 | 0.49 |
| ▸ | TSHR | P16473 | 1/20 | 0.48 |
| ▸ | GSR | P00390 | 2/20 | 0.47 |
| ▸ | L3MBTL1 | Q9Y468 | 1/20 | 0.47 |
| ▸ | SIRT2 | Q8IXJ6 | 2/20 | 0.47 |
| ▸ | SIRT1 | Q96EB6 | 2/20 | 0.47 |
| ▸ | MAPT | P10636 | 1/20 | 0.47 |
| ▸ | GLA | P06280 | 1/20 | 0.47 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL13472212 | 0.89 | SIRT2 (0.56) | THRATHRBKMT2AALDH1A1LMNA | |
| SCHEMBL13472221 | 0.88 | SIRT2 (0.55) | THRATHRBKMT2AALDH1A1LMNA | |
| SCHEMBL9509517 | 0.88 | THRA (0.60) | THRATHRBKMT2AGSR | |
| SCHEMBL3456365 | 0.82 | L3MBTL1 (0.57) | KMT2AALDH1A1KDM4EPARP1L3MBTL1 | |
| SCHEMBL11271365 | 0.81 | THRA (0.55) | THRATHRBKMT2AALDH1A1KDM4E | |
| SCHEMBL30701093 | 0.81 | CTNNB1 (0.55) | THRATHRBKMT2ALMNAKDM4E | |
| SCHEMBL30317739 | 0.81 | THRA (0.55) | THRATHRBKMT2AALDH1A1KDM4E | |
| SCHEMBL12391580 | 0.81 | CTNNB1 (0.55) | THRATHRBKMT2ALMNAKDM4E | |
| SCHEMBL4518276 | 0.81 | PARP1 (0.58) | KMT2AALDH1A1LMNAPARP1L3MBTL1 | |
| SCHEMBL19072807 | 0.80 | THRA (0.53) | THRATHRBKMT2AALDH1A1LMNA |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 21 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20260078117-A1 | COMPOUNDS AND METHODS OF USE | TANGO THERAPEUTICS INC (US) | 2026-03-19 | — | — | US | disclosed |
| US-12304907-B2 | Compounds and methods of use | TANGO THERAPEUTICS, INC. (US) | 2025-05-20 | — | — | US | disclosed |
| US-20240279219-A1 | COMPOUNDS AND METHODS OF USE | TANGO THERAPEUTICS, INC. | 2024-08-22 | — | — | US | disclosed |
| US-20240228478-A1 | COMPOUNDS AND METHODS OF USE | TANGO THERAPEUTICS, INC. | 2024-07-11 | — | — | US | disclosed |
| US-20240228478-A1 | COMPOUNDS AND METHODS OF USE | TANGO THERAPEUTICS, INC. | 2024-07-11 | — | — | US | disclosed |
| EP-3170810-B1 | PYRIDINE DERIVATIVES AND ANTI-MYCOBACTERIAL USE THEREOF | CISEN PHARMACEUTICAL CO LTD (CN) | 2018-09-19 | — | — | EP | disclosed |
| US-9878982-B2 | Pyridine derivatives and anti-mycobacterial use thereof | CISEN PHARMACEUTICAL CO., LTD. (CN) | 2018-01-30 | — | — | US | disclosed |
| US-9878982-B2 | Pyridine derivatives and anti-mycobacterial use thereof | CISEN PHARMACEUTICAL CO., LTD. (CN) | 2018-01-30 | — | — | US | disclosed |
| US-9878982-B2 | Pyridine derivatives and anti-mycobacterial use thereof | CISEN PHARMACEUTICAL CO., LTD. (CN) | 2018-01-30 | — | — | US | disclosed |
| US-20170174628-A1 | PYRIDINE DERIVATIVES AND ANTI-MYCOBACTERIAL USE THEREOF | CISEN PHARMACEUTICAL CO., LTD. (CN) | 2017-06-22 | — | — | US | disclosed |
| US-20170174628-A1 | PYRIDINE DERIVATIVES AND ANTI-MYCOBACTERIAL USE THEREOF | CISEN PHARMACEUTICAL CO., LTD. (CN) | 2017-06-22 | — | — | US | disclosed |
| EP-3170810-A1 | PYRIDINE DERIVATIVES AND ANTI-MYCOBACTERIAL USE THEREOF | Cisen Pharmaceutical Co. Ltd. (CN) | 2017-05-24 | — | — | EP | disclosed |
| EP-3170810-A1 | PYRIDINE DERIVATIVES AND ANTI-MYCOBACTERIAL USE THEREOF | Cisen Pharmaceutical Co. Ltd. (CN) | 2017-05-24 | — | — | EP | disclosed |
| WO-2016008381-A1 | PYRIDINE DERIVATIVES AND ANTI-MYCOBACTERIAL USE THEREOF | 辰欣药业股份有限公司 | 2016-01-21 | — | — | WO | disclosed |
| US-8674136-B2 | Aromatic butan-2-ol compounds and preparation and uses thereof | INSTITUTE OF PHARMACOLOGY AND TOXICOLOGY ACADEMY OF MILITARY MEDICAL SCIENCES P.L.A. CHINA (CN) | 2014-03-18 | — | — | US | disclosed |
| US-8674136-B2 | Aromatic butan-2-ol compounds and preparation and uses thereof | INSTITUTE OF PHARMACOLOGY AND TOXICOLOGY ACADEMY OF MILITARY MEDICAL SCIENCES P.L.A. CHINA (CN) | 2014-03-18 | — | — | US | disclosed |
| US-20130085183-A1 | AROMATIC BUTAN-2-OL COMPOUNDS AND PREPARATION AND USES THEREOF | INSTITUTE OF PHARMACOLOGY AND TOXICOLOGY ACADEMY OF MILITARY MEDICAL SCIENCES P.L.A. CHINA (CN) | 2013-04-04 | — | — | US | disclosed |
| US-20130085183-A1 | AROMATIC BUTAN-2-OL COMPOUNDS AND PREPARATION AND USES THEREOF | INSTITUTE OF PHARMACOLOGY AND TOXICOLOGY ACADEMY OF MILITARY MEDICAL SCIENCES P.L.A. CHINA (CN) | 2013-04-04 | — | — | US | disclosed |
| US-7598423-B2 | Potentiators of glutamate receptors | ELI LILLY AND COMPANY (US) | 2009-10-06 | — | — | US | disclosed |
| US-20080139505-A1 | Potentiators Of Glutamate Receptors | ARRAY BIOPHARMA, INC. | 2008-06-12 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (7 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20080139505-A1 | Potentiators Of Glutamate Receptors | GRM1, GRIN1, GRM2 | THRA 454/4885THRB 501/4885KMT2A 3143/4885 |
| US-20240279219-A1 | COMPOUNDS AND METHODS OF USE | F12, C1R, ABCG2 | THRA 1620/4885THRB 2248/4885KMT2A 4008/4885 |
| US-20170174628-A1 | PYRIDINE DERIVATIVES AND ANTI-MYCOBACTERIAL USE THEREOF | ME3, SSBP1, MDH2 | THRA 3784/4885THRB 3150/4885KMT2A 4504/4885 |
| US-12304907-B2 | Compounds and methods of use | F12, C1R, ABCG2 | THRA 1620/4885THRB 2248/4885KMT2A 4008/4885 |
| US-20240228478-A1 | COMPOUNDS AND METHODS OF USE | F12, C1R, ABCG2 | THRA 1620/4885THRB 2248/4885KMT2A 4008/4885 |
| US-20260078117-A1 | COMPOUNDS AND METHODS OF USE | NR3C2, ADRA1A, CNR1 | THRA 402/4885THRB 995/4885KMT2A 3362/4885 |
| US-20130085183-A1 | AROMATIC BUTAN-2-OL COMPOUNDS AND PREPARATION AND USES THEREOF | TMBIM6, SORD, TBC1D5 | THRA 2210/4885THRB 1129/4885KMT2A 4704/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.